Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer.
Roberto Alva-RuizLavanya YohanathanJennifer A YonkusAmro M AbdelrahmanLindsey A GregoryThorvadur R HalfdanarsonAmit MahipalRobert R McWilliamsWen Wee MaChristopher L HallemeierRondell P GrahamTravis E GrotzRory L SmootSean P ClearyDavid M NagorneyMichael L KendrickMark J TrutyPublished in: Annals of surgical oncology (2021)
CS in patients undergoing NAC for BR/LA pancreatic cancer does not incur oncologic detriment. The incorporation of CS into NAC treatment sequencing may allow a greater proportion of patients to proceed to curative-intent surgery.
Keyphrases
- locally advanced
- neoadjuvant chemotherapy
- rectal cancer
- patients undergoing
- squamous cell carcinoma
- transcription factor
- phase ii study
- radiation therapy
- end stage renal disease
- prognostic factors
- ejection fraction
- sentinel lymph node
- lymph node
- minimally invasive
- coronary artery bypass
- single cell
- prostate cancer
- patient reported outcomes
- radical prostatectomy
- percutaneous coronary intervention
- acute coronary syndrome
- surgical site infection